{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:44Z","timestamp":1788496304171,"version":"build-2803163510"},"reference-count":17,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1297\/cpe.2023-0043","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T17:10:48Z","timestamp":1706375448000},"page":"27-34","source":"Crossref","is-referenced-by-count":1,"title":["Switching to burosumab from conventional therapy in siblings with relatively          well-controlled X-linked hypophosphatemia"],"prefix":"10.1297","volume":"33","author":[{"given":"Shintaro","family":"Senoo","sequence":"first","affiliation":[{"name":"Division of Pediatrics and Perinatology, Faculty of Medicine, Tottori              University, Yonago, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Perinatology, Faculty of Medicine, Tottori              University, Yonago, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Perinatology, Faculty of Medicine, Tottori              University, Yonago, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Osaki","sequence":"additional","affiliation":[{"name":"Rehabilitation Division, Tottori University Hospital, Yonago,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Hanaki","sequence":"additional","affiliation":[{"name":"School of Health Science, Faculty of Medicine, Tottori University, Yonago,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[{"name":"Division of Pediatrics and Perinatology, Faculty of Medicine, Tottori              University, Yonago, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Francis,              F, Hennig,                S, Korn,                B,                Reinhardt,              R, de Jong,                P, Poustka,                A, et al.            The HYP Consortium. A gene (PEX) with            homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic            rickets. Nat Genet          1995;11: 130\u20136.","DOI":"10.1038\/ng1095-130"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Liu,              S, Guo,                R, Simpson,                LG, Xiao,                ZS,              Burnham, CE,                Quarles,            LD. Regulation of            fibroblastic growth factor 23 expression but not degradation by PHEX.            J Biol Chem          2003;278: 37419\u201326.","DOI":"10.1074\/jbc.M304544200"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shimada,              T, Hasegawa,                H,              Yamazaki, Y,                Muto, T,                Hino, R,                Takeuchi,            Y, et al.            FGF-23 is a potent regulator of vitamin D metabolism and phosphate            homeostasis. J Bone Miner Res          2004;19: 429\u201335.","DOI":"10.1359\/JBMR.0301264"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Beck-Nielsen,                SS,                Brock-Jacobsen,              B, Gram,                J, Brixen,                K, Jensen,                TK. Incidence            and prevalence of nutritional and hereditary rickets in southern          Denmark. Eur J Endocrinol          2009;160: 491\u20137.","DOI":"10.1530\/EJE-08-0818"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Endo,              I, Fukumoto,                S, Ozono,                K, Namba,                N, Inoue,                D, Okazaki,                R, et al.            Nationwide survey of fibroblast growth factor 23 (FGF23)-related            hypophosphatemic diseases in Japan: prevalence, biochemical data and            treatment. Endocr J          2015;62: 811\u20136.","DOI":"10.1507\/endocrj.EJ15-0275"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Beck-Nielsen,                SS, Mughal,                Z, Haffner,                D, Nilsson,                O,                Levtchenko,              E, Ariceta,                G, et al.            FGF23 and its role in X-linked hypophosphatemia-related            morbidity. Orphanet J Rare Dis          2019;14: 58.","DOI":"10.1186\/s13023-019-1014-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Haffner,              D, Emma,                F,              Eastwood, DM,                Duplan, MB,                Bacchetta,              J, Schnabel,                D, et al.            Clinical practice recommendations for the diagnosis and management of            X-linked hypophosphataemia. Nat Rev Nephrol          2019;15: 435\u201355.","DOI":"10.1038\/s41581-019-0152-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Carpenter,                TO, Imel,                EA, Holm,                IA, Jan de                Beur, SM,                Insogna,            KL. A clinician\u2019s            guide to X-linked hypophosphatemia. J Bone Miner Res          2011;26: 1381\u20138.","DOI":"10.1002\/jbmr.340"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Carpenter,                TO, Whyte,                MP, Imel,                EA, Boot,                AM, H\u00f6gler,                W,              Linglart, A,              et al. Burosumab Therapy in Children with            X-Linked Hypophosphatemia. N Engl J Med          2018;378: 1987\u201398.","DOI":"10.1056\/NEJMoa1714641"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Imel,              EA, Glorieux,                FH, Whyte,                MP, Munns,                CF, Ward,                LM,              Nilsson, O,              et al. Burosumab versus conventional            therapy in children with X-linked hypophosphataemia: a randomised, active-controlled,            open-label, phase 3 trial. Lancet          2019;393: 2416\u201327.","DOI":"10.1016\/S0140-6736(19)30654-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Whyte,              MP,              Carpenter,            TO, Gottesman,                GS, Mao,                M, Skrinar,                A, San                Martin, J, et            al. Efficacy and safety of burosumab in children            aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2            trial. Lancet Diabetes Endocrinol          2019;7: 189\u201399.","DOI":"10.1016\/S2213-8587(18)30338-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Thacher,                TD,              Fischer, PR,                Pettifor,              JM, Lawson,                JO,                Manaster,              BJ, Reading,                JC.            Radiographic scoring method for the assessment of the severity of            nutritional rickets. J Trop Pediatr          2000;46: 132\u20139.","DOI":"10.1093\/tropej\/46.3.132"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Whyte,              MP, Fujita,                KP,              Moseley, S,                Thompson,              DD,              McAlister,            WH. Validation of            a novel scoring system for changes in skeletal manifestations of hypophosphatasia in            newborns, infants, and children: the radiographic global impression of change            scale. J Bone Miner Res          2018;33: 868\u201374.","DOI":"10.1002\/jbmr.3377"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Thacher,                TD,                Pettifor,              JM, Tebben,                PJ, Creo,                AL,              Skrinar, A,                Mao, M,              et al. Rickets severity predicts clinical            outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets            Severity Score. Bone          2019;122: 76\u201381.","DOI":"10.1016\/j.bone.2019.02.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Namba,              N, Kubota,                T, Muroya,                K, Tanaka,                H,                Kanematsu,              M, Kojima,                M, et al.            Safety and efficacy of Burosumab in pediatric patients with X-linked            hypophosphatemia: a phase 3\/4 open-label trial. J Endocr            Soc          2022;6: bvac021.","DOI":"10.1210\/jendso\/bvac021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. M\u00e4kitie,              O, Doria,                A, Kooh,                SW, Cole,                WG,              Daneman, A,                Sochett,            E. Early            treatment improves growth and biochemical and radiographic outcome in X-linked            hypophosphatemic rickets. J Clin Endocrinol Metab          2003;88: 3591\u20137.","DOI":"10.1210\/jc.2003-030036"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zivi\u010dnjak,                M,              Schnabel, D,                Billing, H,                Staude, H,                Filler, G,                Querfeld,            U, et al.            Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft f\u00fcr            P\u00e4diatrische Endokrinologie and Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie.            Age-related stature and linear body segments in children with X-linked            hypophosphatemic rickets. Pediatr Nephrol          2011;26: 223\u201331.","DOI":"10.1007\/s00467-010-1705-9"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/33\/1\/33_2023-0043\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T23:30:43Z","timestamp":1706916643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/33\/1\/33_2023-0043\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.2023-0043","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"2023-0043"}}